109 related articles for article (PubMed ID: 27182702)
1. Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study.
Sambol NC; Tappero JW; Arinaitwe E; Parikh S
PLoS One; 2016; 11(5):e0154623. PubMed ID: 27182702
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine.
Permala J; Tarning J; Nosten F; White NJ; Karlsson MO; Bergstrand M
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242661
[TBL] [Abstract][Full Text] [Related]
3. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.
Sundell K; Jagannathan P; Huang L; Bigira V; Kapisi J; Kakuru MM; Savic R; Kamya MR; Dorsey G; Aweeka F
Malar J; 2015 Sep; 14():368. PubMed ID: 26403465
[TBL] [Abstract][Full Text] [Related]
4. Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children.
Chotsiri P; Zongo I; Milligan P; Compaore YD; Somé AF; Chandramohan D; Hanpithakpong W; Nosten F; Greenwood B; Rosenthal PJ; White NJ; Ouédraogo JB; Tarning J
Nat Commun; 2019 Jan; 10(1):480. PubMed ID: 30696903
[TBL] [Abstract][Full Text] [Related]
5. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
Wallender E; Zhang N; Conrad M; Kakuru A; Muhindo M; Tumwebaze P; Kajubi R; Mota D; Legac J; Jagannathan P; Havlir D; Kamya M; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530597
[TBL] [Abstract][Full Text] [Related]
6. Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial.
Muhindo MK; Jagannathan P; Kakuru A; Opira B; Olwoch P; Okiring J; Nalugo N; Clark TD; Ruel T; Charlebois E; Feeney ME; Havlir DV; Dorsey G; Kamya MR
Lancet Infect Dis; 2019 Sep; 19(9):962-972. PubMed ID: 31307883
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria.
Lwin KM; Phyo AP; Tarning J; Hanpithakpong W; Ashley EA; Lee SJ; Cheah P; Singhasivanon P; White NJ; Lindegårdh N; Nosten F
Antimicrob Agents Chemother; 2012 Mar; 56(3):1571-7. PubMed ID: 22252804
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.
Creek DJ; Bigira V; McCormack S; Arinaitwe E; Wanzira H; Kakuru A; Tappero JW; Sandison TG; Lindegardh N; Nosten F; Aweeka FT; Parikh S
J Infect Dis; 2013 Jun; 207(11):1646-54. PubMed ID: 23447696
[TBL] [Abstract][Full Text] [Related]
9. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz.
Wallender E; Vucicevic K; Jagannathan P; Huang L; Natureeba P; Kakuru A; Muhindo M; Nakalembe M; Havlir D; Kamya M; Aweeka F; Dorsey G; Rosenthal PJ; Savic RM
J Infect Dis; 2018 Mar; 217(6):964-972. PubMed ID: 29272443
[TBL] [Abstract][Full Text] [Related]
10. Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention.
Bergstrand M; Nosten F; Lwin KM; Karlsson MO; White NJ; Tarning J
Sci Transl Med; 2014 Oct; 6(260):260ra147. PubMed ID: 25355697
[TBL] [Abstract][Full Text] [Related]
11. Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.
Whalen ME; Kajubi R; Chamankhah N; Huang L; Orukan F; Wallender E; Kamya MR; Dorsey G; Jagannathan P; Rosenthal PJ; Mwebaza N; Aweeka FT
Clin Pharmacol Ther; 2019 Dec; 106(6):1310-1318. PubMed ID: 31173649
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.
Hoglund RM; Workman L; Edstein MD; Thanh NX; Quang NN; Zongo I; Ouedraogo JB; Borrmann S; Mwai L; Nsanzabana C; Price RN; Dahal P; Sambol NC; Parikh S; Nosten F; Ashley EA; Phyo AP; Lwin KM; McGready R; Day NP; Guerin PJ; White NJ; Barnes KI; Tarning J
PLoS Med; 2017 Jan; 14(1):e1002212. PubMed ID: 28072872
[TBL] [Abstract][Full Text] [Related]
13. Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children.
Wallender E; Ali AM; Hughes E; Kakuru A; Jagannathan P; Muhindo MK; Opira B; Whalen M; Huang L; Duvalsaint M; Legac J; Kamya MR; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
Nat Commun; 2021 Nov; 12(1):6714. PubMed ID: 34795281
[TBL] [Abstract][Full Text] [Related]
14. Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy.
Chotsiri P; Gutman JR; Ahmed R; Poespoprodjo JR; Syafruddin D; Khairallah C; Asih PBS; L'lanziva A; Otieno K; Kariuki S; Ouma P; Were V; Katana A; Price RN; Desai M; Ter Kuile FO; Tarning J
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33361303
[TBL] [Abstract][Full Text] [Related]
15. Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia.
Vanachayangkul P; Lon C; Spring M; Sok S; Ta-Aksorn W; Kodchakorn C; Pann ST; Chann S; Ittiverakul M; Sriwichai S; Buathong N; Kuntawunginn W; So M; Youdaline T; Milner E; Wojnarski M; Lanteri C; Manning J; Prom S; Haigney M; Cantilena L; Saunders D
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193647
[TBL] [Abstract][Full Text] [Related]
16. Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention.
Hong H; Aslam-Mir U; Kajubi R; Wallender E; Mwebaza N; Dorsey G; Rosenthal PJ; Aweeka FT; Huang L
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0142722. PubMed ID: 36916944
[TBL] [Abstract][Full Text] [Related]
17. Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women.
Hughes E; Wallender E; Kajubi R; Jagannathan P; Ochieng T; Kakuru A; Kamya MR; Clark TD; Rosenthal PJ; Dorsey G; Aweeka F; Savic RM
Clin Infect Dis; 2022 Aug; 75(3):406-415. PubMed ID: 34864925
[TBL] [Abstract][Full Text] [Related]
18. Dihydroartemisinin-piperaquine or sulphadoxine-pyrimethamine for the chemoprevention of malaria in children with sickle cell anaemia in eastern and southern Africa (CHEMCHA): a protocol for a multi-centre, two-arm, double-blind, randomised, placebo-controlled superiority trial.
Nkosi-Gondwe T; Robberstad B; Opoka R; Kalibbala D; Rujumba J; Galileya LT; Akun P; Nambatya W; Ssenkusu J; TerKuile F; Phiri K; Idro R
Trials; 2023 Apr; 24(1):257. PubMed ID: 37016392
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.
Sambol NC; Yan L; Creek DJ; McCormack SA; Arinaitwe E; Bigira V; Wanzira H; Kakuru A; Tappero JW; Lindegardh N; Tarning J; Nosten F; Aweeka FT; Parikh S
Clin Pharmacol Ther; 2015 Jul; 98(1):87-95. PubMed ID: 25732044
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.
Kajubi R; Huang L; Jagannathan P; Chamankhah N; Were M; Ruel T; Koss CA; Kakuru A; Mwebaza N; Kamya M; Havlir D; Dorsey G; Rosenthal PJ; Aweeka FT
Clin Pharmacol Ther; 2017 Sep; 102(3):520-528. PubMed ID: 28187497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
